News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]

Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.

Morphic appoints Simon Cooper as CMO [Seeking Alpha]

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer [Yahoo! Finance]

Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $100.00 price target on the stock.

2/28/2024

04:01 pm

kros

-0.8%

BEAT

11/6/2023

08:00 am

kros

-0.8%

BEAT

8/7/2023

08:00 am

kros

-1.7%

BEAT

Form S-3ASR Keros Therapeutics, Inc.

Form ARS Keros Therapeutics, Inc. For: Dec 31

Form DEFA14A Keros Therapeutics, Inc.

Form DEF 14A Keros Therapeutics, Inc. For: May 30

Form 8-K Keros Therapeutics, Inc. For: Mar 14

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}